SCHEMBL27901583

SCHEMBL27901583

O=C(Nc1cccc(C(F)(F)F)c1)c1ccccc1C(=O)c1ccc2n[c][nH]c2c1

nearest known ligand 0.55

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 18/20 0.55
▸ P2RX1 P51575 1/20 0.52
▸ PTGS1 P23219 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4469804 0.87 HTT (0.46) —
SCHEMBL3848659 0.85 MEN1 (0.52) RXFP1
SCHEMBL4459109 0.85 RAF1 (0.41) RXFP1
SCHEMBL4462942 0.85 FADS1 (0.49) P2RX1
SCHEMBL27919273 0.82 FADS1 (0.51) RXFP1
SCHEMBL4464511 0.80 MAPT (0.44) —
SCHEMBL1792255 0.80 RAF1 (0.57) RXFP1
SCHEMBL1469077 0.77 RXFP1 (0.49) RXFP1P2RX1
SCHEMBL4473204 0.77 NPC1 (0.41) RXFP1
SCHEMBL3855951 0.74 NPSR1 (0.48) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101959516-B Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer EXELIXIS INC 2013-05-08 — — CN disclosed
Send feedback